ArticleScientific reports2020
The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Literature review analysis of aortitis induced by granulocyte-colony stimulating factor.Frontiers in pharmacology · 2024Pooled it
- Pembrolizumab-Associated Aortitis in a Patient With Triple-Negative Breast Cancer: A Case Report.Cureus · 2026Article
- Successful Treatment of Granulocyte Colony-Stimulating Factor-Related Aortitis in Prostate Cancer.IJU case reports · 2026Article
- Prolonged myopathy and musculoskeletal symptoms following filgrastim in a 43-Year-Old female stem cell donor: a case-based review.Rheumatology international · 2025Review
- G-CSF-induced Aortitis Mimicking TIPIC Syndrome.Internal medicine (Tokyo, Japan) · 2025Article
- Article
- Pegfilgrastim (Neulasta)-induced acute aortitis: a case report.European heart journal. Case reports · 2025Article
- Aortitis after granulocyte-colony stimulating factor administration: A case report.Biomedical reports · 2025Article
- Clinical Insights Into Aortitis Following Granulocyte Colony-Stimulating Factor Use in an Older Male Patient.Cureus · 2025Article
- Granulocyte colony-stimulating factor-associated aortitis in a man with advanced prostate cancer.IJU case reports · 2025Article
- Aortitis after switching short-acting granulocyte colony-stimulating factors in a lymphoma patient with HLA-B52.International journal of hematology · 2024Article
- Article
- Aortitis after administration of pegfilgrastim to a healthy donor for peripheral blood stem cell collection.International journal of hematology · 2023Article
- Granulocyte Colony-stimulating Factor-associated Aortitis on Gallium Scintigraphy.Internal medicine (Tokyo, Japan) · 2023Article
- Aortitis Associated with Prophylactic Short-acting Granulocyte Colony-stimulating Factor Administration: A Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2023Review
- Pegfilgrastim-induced vasculitis of the subclavian and basilar artery complicated by subarachnoid hemorrhage in a breast cancer patient: a case report and review of the literature.Surgical case reports · 2022Article
- Granulocyte colony stimulating factor (G-CSF)-induced aortitis in a patient undergoing adjuvant chemotherapy for breast cancer.BMJ case reports · 2022Article
- Article
- Imaging findings of granulocyte colony-stimulating factor-producing tumors: a case series and review of the literature.Japanese journal of radiology · 2021Review
- Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report.Surgical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although PEGylated filgrastim-induced aortitis is very rare and unknown clinically, some cases were reported and increasing, especially in breast cancer patients. The present study investigated the prevalence, clinical features and treatment of aortitis induced by PEGylated filgrastim in patients with breast cancer. A total of 2068 consecutive patients who underwent neoadjuvant/adjuvant chemotherapy with PEGylated filgrastim for breast cancer were enrolled. From the medical record, clinical, laboratory, medication, and imaging evaluation findings were collected. PEGylated filgrastim-induced aortitis was established in 0.3% of the study population. Common clinical presentations included extremely high fever and chest/back pain with high levels of inflammatory markers without any signs of infection. Contrast-enhanced computed tomography scans revealed typical enhancing wall thickening and periaortic soft tissue infiltration at various levels of aorta. All patients improved rapidly after treatment with modest doses of prednisolone (0.5 mg/kg/day) without any complications. Clinicians should be aware of aortitis as a possible complication of granulocyte-colony stimulating factor therapy, especially PEGylated filgrastim, given the frequent misdiagnoses in neutropenic patients undergoing chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.